Tassopoulos and colleagues designed a clinical trial aimed at establishing whether treatment with interferon in acute hepatitis B could modify the severity and duration of symptoms, the clearance of viral markers, or the titre of neutralising antibodies.' The study included 100 patients with acute hepatitis B who were randomised to three groups. Group I consisted of 34 patients who received 3 million units (MU) of interferon alfa-2b three times weekly for three weeks. Group II included 33 patients treated with 10 MU of interferon alfa-2b three times weekly for three weeks, and group III, with 33 patients, received placebo for the same period of time.
Interferon was well tolerated in all patients, even those with a prolonged prothrombin time or marked jaundice. None of the patients treated with IFN alfa-2b experienced a flare up of the disease or developed encephalopathy. Although the overall clinical, biochemical, and serological outcome was similar in the three groups, patients in group I, who received 3 MU of interferon, showed a clinical improvement in the signs and symptoms of acute hepatitis appreciably earlier than those in the control group. At the end of treatment, ALT activities and bilirubin values were similar between groups, although in group II, that is in patients treated with 10 MU of IFN, ALT activities returned to normal earlier.' There was no difference in the clearance rate of HBsAg between groups, but women in group I eliminated this marker more rapidly than men. HBV-DNA seemed to become negative in Group I earlier than in the other two groups, although there was not a statistically significant difference. In group I, 91.2% of patients were HBV-DNA positive at onset compared with only 17-6% after two weeks of treatment.
The group that received 10 MU of interferon (Group II) showed higher geometric mean titre (85 1 IUll) than patients treated with 3 MU (40 7 IU/l) or placebo (355 IU/l).'
In summary, the study by Tassopoulos The study by Omata and colleagues5 also deserves emphasis. In a controlled trial of 25 patients, 11 were treated with a interferon for four weeks while 14 patients served as controls. One year after treatment, seven of 11 patients (64%) had normal ALT activities, compared with only one of the controls (7%). After this initial trial, three of four patients who did not respond to interferon achieved normal ALT activities after a second course of treatment. After three years of follow up, HCV-RNA by polymerase chain reaction had become negative in 10 of 11 patients treated with 13 interferon, suggesting that interferon normalises ALT activities by inhibiting HCV replication.
In our hospital, we designed a randomised, controlled trial of interferon alfa in 28 patients with acute post-transfusion hepatitis C;6 19 were heart surgery patients, four were from general surgery, two from urology, two from gynaecology, and one from internal medicine.
Diagnosis of acute post-transfusion non-A, non-B hepatitis was based on standard criteria, and other forms of viral hepatitis were serologically excluded.
The objective of the study was to assess the toleration of the treatment, efficacy in returning ALT activities to normal, and the influence on the histological outcome of the disease. Fifteen patients were randomised to receive 3 MU of IFN alfa-2b three times weekly subcutaneously for 12 weeks, while 13 patients received no treatment, and acted as controls. There were no differences between the groups in terms of age, sex, anti-HCV positivity, incubation period, peak ALT, and the presence of jaundice. Serum samples from all patients were taken weekly during the first month, bi-weekly for the next two months, and then once a month until completing one year of follow up. A liver biopsy was performed at six and 12 months of follow up. Treatment was well tolerated in all patients. Only 40% of patients had mild flu-like symptoms, and in no case was treatment stopped or the dose of IFN reduced. Figure 1 shows the serological results of the study. Before treatment, 73% of patients in the treated group tested positive in the first generation anti-HCV ELISA, and 80% in the second generation ELISA; all but one patient (930/o) had HCV-RNA detected by polymerase chain reaction using a primer of the 5' UTR region. All patients in the control group were anti-HCV positive.
At the end of treatment (three months) 
